Recombinant Human TFPI Protein，His

Tissue Factor Pathway Inhibitor (TFPI) is a critical protein that regulates hemostasis by inhibiting the extrinsic pathway of coagulation. Its primary function is to bind to the tissue factor-factor VIIa complex, thereby preventing the activation of factor X and ultimately inhibiting thrombin generation. The importance of TFPI in maintaining the balance between coagulation and fibrinolysis has made it a focal point of research, particularly in the context of thrombotic disorders and cardiovascular diseases. Studies have shown that altered levels of TFPI can contribute to various pathological conditions, including venous thromboembolism and atherosclerosis. Additionally, TFPI has been implicated in cancer biology, where tumor cells may exploit coagulation pathways for growth and metastasis. The production of recombinant TFPI proteins has provided a valuable tool for both therapeutic and research applications, allowing for the examination of its biological functions and potential as a therapeutic agent. Given the complexities of coagulation pathways and the role of TFPI as a natural inhibitor, ongoing research aims to elucidate its mechanisms of action and explore its possibilities in clinical applications, including the development of novel anticoagulant therapies. This area of study holds promise for improving outcomes in patients at risk for thrombotic events, making TFPI an important target in the fields of hematology and cardiology.